申请人:Chan Tak-Hang
公开号:US20080176931A1
公开(公告)日:2008-07-24
(−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R
11
, R
12
, R
13
, R
21
, R
22
, R
2
, R
3
, and R
4
are each independently selected from the group consisting of —H, and C
1
to C
10
acyloxyl group; and R
5
is selected from the group consisting of —H, C
1
-C
10
-alkyl, C
2
-C
10
-alkenyl, C
2
-C
10
-alkynyl, C
3
-C
7
-cycloalkyl, phenyl, benzyl and C
3
-C
7
-cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R
11
, R
12
, R
13
, R
21
, R
22
, R
2
, R
3
and R
4
is —H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth.
(-)-EGCG是最丰富的儿茶素之一,被发现具有化学预防和抗癌作用。然而,(-)-EGCG至少存在一个限制:其生物利用度较低。本发明提供了一般化学式如下的化合物,其中R11、R12、R13、R21、R22、R2、R3和R4各自独立地选择自-H和C1到C10酰氧基的群组成;而R5选择自-H、C1-C10烷基、C2-C10烯基、C2-C10炔基、C3-C7环烷基、苯基、苄基和C3-C7环烯基,而最后提到的7个基团中的每一个都可以用任意组合的1到6个卤素原子取代;其中至少有一个是R11、R12、R13、R21、R22、R2、R3和R4中的-H,这些化合物比其非保护的对应物更有效,可用作蛋白酶体抑制剂来减少肿瘤细胞生长。